Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme (Q36614009)

15 August 2017

1 reference

title

Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme (English)

1 reference

15 August 2017

1 reference

Amith Panner

1

1 reference

15 August 2017

Andrew T Parsa

series ordinal

2

1 reference

15 August 2017

Russell O Pieper

series ordinal

3

1 reference

15 August 2017

publication date

1 September 2006

1 reference

Expert Review of Anticancer Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

6

1 reference

15 August 2017

issue

9

1 reference

15 August 2017

page(s)

1313-1322

1 reference

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Akt regulates growth by directly phosphorylating Tsc2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Rheb promotes cell growth as a component of the insulin/TOR signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Regulation of translation initiation by FRAP/mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Identification of TOR signaling complexes: more TORC for the cell growth engine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Incidence, mechanism and prognostic value of activated AKT in pancreas cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

TSC2 regulates VEGF through mTOR-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

eIF-4E expression and its role in malignancies and metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Targeting the molecular target of rapamycin (mTOR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Targeting HIF-1 for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Apo2L/TRAIL and its death and decoy receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Shared pathways: death receptors and cytotoxic drugs in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

NF-kappaB at the crossroads of life and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Promoting apoptosis as a strategy for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1313

10.1586/14737140.6.9.1313

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference